National Kidney Foundation holding patient-focused meeting with FDA

On Friday, the National Kidney Foundation (NKF) will lead a patient-focused drug development (PFDD) meeting on complement 3 glomerulopathy (C3G), a rare kidney disease, in the hopes of advancing development of innovative treatments for the disease.

The meeting will facilitate discussions between patients, caregivers, physicians and FDA representatives about the challenges C3G patients face and the need for effective therapies. The PFDD will also cover challenges in designing clinical trials for C3G...